Skip to main content
Press Releases

COVID-19 Resources

Resources are updated on an ongoing basis. Last updated September 17, 2025.

People discussing a print out around a table

Press Releases

2025

8/27 – Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

8/22 – Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

7/30 – Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

7/25 – EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1

7/10 – Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease

5/31 – Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

5/23 – Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

5/21 – Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19

1/24 – Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union

2024

12/20 – Moderna – The Hidden Cost of COVID – Long COVID's Impact on the Workforce

9/30 – Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna's mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

9/17 – Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

9/5 – EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

9/3 – Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1

9/2 – Taiwan Food & Drug Administration Approves Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

8/29 – Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination

8/23 – Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

8/22 – Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2

8/22 – Celebrating U.S. FDA Approval of Our Updated COVID-19 Vaccine

8/15 – COVID-19 Summer Surge – Three Things to Know

7/31 – Understanding Long COVID’s Impact on the Workforce

7/8 – Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna's mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines

7/2 – Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine

6/13 – Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company's Next Generation COVID-19 Vaccine

6/10 – Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

6/7 – Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

4/22 – Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign

3/26 – Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

2023

10/24 – Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19

10/4 – Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19

9/14 – EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in The European Union

9/11 – Our Continued Innovation at Work – Celebrating U.S. FDA Approval of Our Updated COVID-19 Vaccine

9/11 – Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine

9/6 – Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86

9/6 – 3 Things to Know About the 2023-2024 COVID-19 Season

7/17 – Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

7/3 – Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

6/29 – MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE

6/22 – Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine

5/24 – Leveraging 13 Years of Investment in mRNA Innovation for Future Pandemic Preparedness

2/17 – Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

2022

12/16 – EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna's BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union

12/8 – Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

11/14 – Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

11/4 – Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

11/1 – Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

10/19 – EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union

10/19 – 90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster

10/17 – Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries

10/12 – Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

9/28 – European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

9/12 – Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

9/11 – Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines

9/1 – Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine

9/1 – EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

8/31 – Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older

8/30 – Therapeutic Goods Administration Provisionally Approves Moderna's Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia

8/23 – Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222

8/22 – Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada

8/15 – Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK

8/9 – Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses

7/29 – Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses

7/22 – EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

7/18 – Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years

7/14 – Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)

7/11 – Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster

6/22 – Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5

6/17 – Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older

6/8 – Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron

6/2 – Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement

5/31 – Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

4/29 – Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union

4/28 – Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

4/19 – Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform

3/29 – Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273

3/23 – Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint

3/21 – Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine

3/17 – Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.

3/17 – Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)

3/16 – Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine

3/10 – Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate

2/24 – EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union

2/16 – Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)

2/8 – Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine

2021

12/27 – Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022

12/27 – Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna's COVID-19 Vaccine or Updated Booster Candidate in 2022

12/20 – Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

12/13 – Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

12/10 – Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

12/01 – Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna's COVID-19 Vaccine in 2022 and 2023

11/26 – Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

11/19 – U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna's COVID-19 Vaccine

11/19 – Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older

11/17 – Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years

11/16 – Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries

11/15 – Health Canada Authorizes Booster Dose of Moderna's COVID-19 Vaccine in Individuals 18 Years of Age and Older

11/09 – Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years

10/31 – Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents

10/29 – Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

10/26 – Moderna Announces Swissmedic Authorizes Booster Dose of Moderna's COVID-19 Vaccine

10/26 – Moderna Announces Memorandum of Understanding to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union

10/25 – Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age

10/25 – Moderna Announces European Medicines Agency's Committee for Medicinal Products for Human Use Recommends Booster Dose of Moderna's COVID-19 Vaccine in the European Union

10/20 – Moderna Announces FDA Authorization of a Booster Dose of Moderna's COVID-19 Vaccine in the U.S.

10/14 – Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna's COVID-19 Vaccine in the U.S.

10/12 – Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna's COVID-19 Vaccine for Low Income Countries in First Half of 2022

10/07 – Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year

10/05 – Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

9/24 – Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine

9/16 – Moderna Announces Health Canada Approves its COVID-19 Vaccine

9/15 – Moderna Highlights New Clinical Data on its COVID-19 Vaccine

9/08 – Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine

9/03 – Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster

9/01 – Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster

8/25 – Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine

8/16 – Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna's COVID-19 Vaccine in 2022, in 2023 and in 2024

8/13 – Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals

8/12 – Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months

8/09 – Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna's COVID-19 Vaccine

7/23 – EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union

7/22 – Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023

7/20 – Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022

7/12 – Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine

7/01 – Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency

6/29 – Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India

6/29 – Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India

6/22 – European Commission Purchases Additional 150 Million Doses of Moderna's COVID-19 Vaccine for Delivery in 2022

6/16 – U.S. Government Purchases Additional 200 Million Doses of Moderna's COVID-19 Vaccine

6/15 – Moderna and Magenta Partner to Distribute Moderna's COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates

6/14 – Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland

6/11 – Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna's COVID-19 Vaccine in Saudi Arabia

6/10 – Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States

6/07 – Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union

6/07 – Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents

6/07 – Moderna and Medison Pharma Partner to Commercialize Moderna's COVID-19 Vaccine Across Central Eastern Europe and Israel

6/03 – Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine

6/02 – UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

6/01 – Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine

6/01 – Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna's COVID-19 Vaccine

5/27 – Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day

5/25 – Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June

5/22 – Moderna and South Korea Explore Collaboration on mRNA Vaccines

5/22 – Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine

5/21 – Ministry of Food and Drug Safety of South Korea (MFDS) Authorizes Moderna's COVID-19 Vaccine

5/21 – Japan's Ministry of Health, Labour and Welfare (MHLW) Approves Moderna's COVID-19 Vaccine

5/12 – Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine

5/06 – Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses

5/05 – Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

5/03 – Moderna Announces Supply Agreement with Gavi for up to 500 Million Doses of COVID-19 Vaccine Moderna for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

4/30 – Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine

4/29 – Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022

4/26 – Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

4/20 – Moderna Announces New Supply Agreement with Israel for 2022

4/13 – Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day

4/07 – Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine

4/06 – Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna's COVID-19 Vaccine and Clinical Portfolio

4/01 – Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine

3/29 – Moderna Announces Shipment of 100 Millionth Dose of its COVID-19 Vaccine to the U.S. Government

3/22 – Moderna Announces New Supply Agreement with the Philippines for 7 Million Additional Doses of COVID-19 Vaccine Moderna

3/16 – Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population

3/15 – First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna's Next Generation COVID-19 Vaccine

3/10 – Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates

3/08 – Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

3/06 – Moderna Announces Supply Agreement to Provide 13 Million Doses of COVID-19 Vaccine Moderna to the Philippines

3/05 – Moderna Announces New Drug Application Submitted to Import and Distribute Moderna's COVID-19 Vaccine Candidate in Japan

2/24 – Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study

2/24 – Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine

2/17 – European Commission Purchases Additional 150 Million Doses of COVID-19 Vaccine Moderna

2/16 – Moderna Provides U.S. COVID-19 Vaccine Supply Update

2/12 – Canada Purchases Additional 4 Million Doses of Moderna's COVID-19 Vaccine

2/11 – U.S. Government Purchases Additional 100 Million Doses of Moderna's COVID-19 Vaccine

2/11 – Qatar Ministry of Public Health Issues Emergency Use Authorization for COVID-19 Vaccine Moderna

2/09 – Moderna Announces COVID-19 Vaccine Supply Agreements with the Government of Taiwan for 5 Million Doses and the Government of Colombia for 10 Million Doses

2/03 – Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use

2/03 – Moderna Announces Amendment to Supply Agreement with Switzerland for an Additional 6 Million Doses of COVID-19 Vaccine Moderna

1/27 – Moderna Confirms Discussions with U.S. Government for Additional 100 Million Doses of the Moderna COVID-19 Vaccine

1/25 – Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25

1/25 – Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa

1/21 – Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda

1/12 – Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland

1/08 – United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna

1/06 – European Commission Authorizes COVID-19 Vaccine Moderna in Europe

1/04 – Moderna Provides COVID-19 Vaccine Supply Update

1/04 – Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

2020

12/31 – Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea

12/31 – Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine

12/30 – Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U.S.

12/29 – Moderna Confirms Discussions With the Government of South Korea to Supply South Korea With 40 Million Doses of COVID-19 Vaccine

12/23 – Health Canada Authorizes Moderna COVID-19 Vaccine in Canada

12/19 – U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna's COVID-19 Vaccine for Persons 18 Years and Older

12/18 – Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.

12/18 – European Commission Exercises Option for Additional 80 Million Doses of Moderna's COVID-19 Vaccine Candidate

12/17 – Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna's Vaccine Against COVID-19 in the United States

12/14 – Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)

12/11 – U.S. Government Exercises 1st Option for Additional 100 Million Doses of Moderna's COVID-19 Vaccine Candidate

12/10 – Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents

12/08 – Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

12/07 – Canada Exercises Increased Option for Total of 40 Million Doses of mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

12/04 – Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

12/03 – Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate

11/30 – Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

11/29 – Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

11/25 – Moderna Announces the European Commission's Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

11/17 – Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use

11/17 – European Medicines Agency Begins Rolling Review of Moderna's mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

11/16 – Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

11/16 – Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures

11/13 – Swissmedic Begins Rolling Review of Moderna's mRNA Vaccine Against COVID-19 (mRNA-1273)

11/11 – Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)

10/29 – Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

10/27 – UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna's mRNA Vaccine Against COVID-19 (mRNA-1273)

10/26 – Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)

10/22 – Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

10/14 – Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)

10/13 – Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)

10/8 – DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics

9/29 – Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

9/22 – Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

9/8 – Biopharma Leaders Unite To Stand With Science

8/28 – Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

8/26 – Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting

8/24 – Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

8/11 – Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

7/28 – Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

7/27 – Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins

7/26 – Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

7/14 – Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)

7/09 – Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate

7/08 – Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)

6/25 – Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate

6/11 – Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19

5/29 – Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

5/18 – Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

5/15 – Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House's Operation Warp Speed Initiative

5/12 – Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

5/01 – Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna's Vaccine (mRNA-1273) Against Novel Coronavirus

4/27 – Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

4/16 – Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

3/29 – Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development

3/16 – Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

2/24 – Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study